HUP0104745A2 - Csípőbél epesav transzport inhibitorok és epesav elvonószerek kombinációi szív-érrendszeri indikációkhoz - Google Patents

Csípőbél epesav transzport inhibitorok és epesav elvonószerek kombinációi szív-érrendszeri indikációkhoz

Info

Publication number
HUP0104745A2
HUP0104745A2 HU0104745A HUP0104745A HUP0104745A2 HU P0104745 A2 HUP0104745 A2 HU P0104745A2 HU 0104745 A HU0104745 A HU 0104745A HU P0104745 A HUP0104745 A HU P0104745A HU P0104745 A2 HUP0104745 A2 HU P0104745A2
Authority
HU
Hungary
Prior art keywords
bile acid
combinations
transport inhibitors
cardiovascular indications
ileal
Prior art date
Application number
HU0104745A
Other languages
English (en)
Inventor
Kevin C. Glenn
Bradley T. Keller
Joseph R. Schuh
Original Assignee
G. D. Searle Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26811681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0104745(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by G. D. Searle Llc filed Critical G. D. Searle Llc
Publication of HUP0104745A2 publication Critical patent/HUP0104745A2/hu
Publication of HUP0104745A3 publication Critical patent/HUP0104745A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

A tal lm ny szív-érrendszeri ter pi s vegyületek kombin ciót ismertetiszív-érrendszeri betegségek, ezen belül hiperkoleszterinémia,érszűkület vagy hiperlipidémia megelőzésére vagy kezelésére. Az ismertetett kombin ciók egy csípőbél-epesav transzportinhibitort és egy epesav elvonószert tartalmaznak. Ó
HU0104745A 1998-12-23 1999-12-17 Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications HUP0104745A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11395598P 1998-12-23 1998-12-23
US14304399P 1999-07-07 1999-07-07
PCT/US1999/027949 WO2000038728A1 (en) 1998-12-23 1999-12-17 Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications

Publications (2)

Publication Number Publication Date
HUP0104745A2 true HUP0104745A2 (hu) 2002-04-29
HUP0104745A3 HUP0104745A3 (en) 2003-01-28

Family

ID=26811681

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104745A HUP0104745A3 (en) 1998-12-23 1999-12-17 Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications

Country Status (24)

Country Link
US (2) US6562860B1 (hu)
EP (1) EP1140190B1 (hu)
JP (1) JP2002533414A (hu)
KR (1) KR20010102965A (hu)
CN (1) CN1338945A (hu)
AR (1) AR022022A1 (hu)
AT (1) ATE228012T1 (hu)
AU (1) AU776953B2 (hu)
BR (1) BR9916484A (hu)
CA (1) CA2356156A1 (hu)
CZ (1) CZ20012345A3 (hu)
DE (1) DE69904079T2 (hu)
DK (1) DK1140190T3 (hu)
EA (1) EA004877B1 (hu)
ES (1) ES2189529T3 (hu)
HK (1) HK1044292A1 (hu)
HU (1) HUP0104745A3 (hu)
IL (1) IL143943A0 (hu)
MX (1) MXPA01006470A (hu)
NO (1) NO20013159L (hu)
NZ (1) NZ512535A (hu)
PL (1) PL348609A1 (hu)
PT (1) PT1140190E (hu)
WO (1) WO2000038728A1 (hu)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
CN1273144C (zh) * 2000-11-28 2006-09-06 三菱制药株式会社 蓄积性含氯化合物的排泄促进剂
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
MXPA03009562A (es) * 2001-04-18 2004-02-12 Genzyme Corp METODO PARA TRATAR EL SiNDROME X CON POLIAMINAS ALIFATICAS.
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
TWI331143B (en) 2001-09-08 2010-10-01 Astrazeneca Uk Ltd Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
PT2637646T (pt) 2010-11-08 2016-08-17 Albireo Ab Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar
AU2011326871B2 (en) 2010-11-08 2015-02-12 Albireo Ab IBAT inhibitors for the treatment of liver diseases
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
SG11201401816SA (en) * 2011-10-28 2014-05-29 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
EA201891154A1 (ru) 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
MX2015013196A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
KR20160002773A (ko) 2013-03-15 2016-01-08 루메나 파마수티컬즈, 인코포레이티드 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
JP6751020B2 (ja) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CN108601745B (zh) 2016-02-09 2021-12-07 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
WO2017138877A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
ES2942443T3 (es) 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
TWI823954B (zh) 2018-06-20 2023-12-01 瑞典商艾爾比瑞歐公司 奧德維希百(odevixibat)之結晶修飾物
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CA3127408A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP7504109B2 (ja) 2019-02-06 2024-06-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
BR112021015809A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Resposta dependente de genótipo e dose a um asbti em pacientes com deficiência de bomba de exportação de sal biliar
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023504647A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
TW202134222A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
AR120682A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
MX2022006731A (es) 2019-12-04 2022-06-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar.
JP2023504644A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
PT4069360T (pt) 2019-12-04 2024-03-06 Albireo Ab Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar
JP2023504643A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CN116157389A (zh) 2020-08-03 2023-05-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3253157A (en) 1963-02-08 1966-05-24 Robotron Corp Timing circuit for actuating a load in accurate relationship to two inputs
US3287370A (en) 1965-06-08 1966-11-22 Mcneilab Inc Tetrahydrobenzothiepins
US3389144A (en) 1965-06-08 1968-06-18 Mcneilab Inc 5-pyridyl-2, 3, 4, 5-tetrahydrobenzothiepin-5-ols
DE1593760A1 (de) 1967-02-01 1972-06-08 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer Benz-epinderivate
US3444176A (en) 1967-04-28 1969-05-13 Mcneilab Inc Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
FR2077733B1 (hu) 1970-02-10 1973-03-16 Roussel Uclaf
US3694446A (en) 1970-02-24 1972-09-26 William J Houlihan 5-(substituted-benzyl)-benzocycloheptenes and-1-benzthiepines
US3692895A (en) 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (de) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
US4002750A (en) 1972-04-28 1977-01-11 Carlo Erba S.P.A. Pyrazine 4-oxide derivatives and process for their preparation
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
US3962261A (en) 1974-02-04 1976-06-08 Warner-Lambert Company 2,3,4,5-tetra hydro-5-oxo-1-benzothiepi n-4-carboxamide 1,1-dioxides
FR2260569B1 (hu) 1974-02-08 1978-06-16 Ugine Kuhlmann
JPS5612114B2 (hu) 1974-06-07 1981-03-18
SE420725B (sv) 1974-09-26 1981-10-26 Ciba Geigy Ag Sett att framstella 2,3-dihydro-1-benstiepin-4-karboxylsyraamider
US4251526A (en) 1977-10-31 1981-02-17 Mccall John M 2-Benzothiepins and compositions and methods of use therefore
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DE2928096A1 (de) 1979-07-12 1981-02-05 Basf Ag Magnetischer aufzeichnungstraeger
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
AU548253B2 (en) 1981-05-11 1985-12-05 Pierre Fabre S.A. Benzoxepine derivatives and sulphur and nitrogen analogues thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4559332A (en) 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
JPS6322056A (ja) 1986-04-30 1988-01-29 サンド・アクチエンゲゼルシヤフト オレフイン性化合物の製造法
AU597671B2 (en) 1986-06-20 1990-06-07 Suntory Limited 2-Phenylbenzoxepin derivative
WO1989001477A1 (en) 1987-08-19 1989-02-23 E.I. Du Pont De Nemours And Company Process for preparing sulfonylurea salts
DE3835291A1 (de) 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
US5158943A (en) 1988-11-21 1992-10-27 Takeda Chemical Industries, Ltd. Sulfur-containing heterocyclic compounds
DE3901527A1 (de) 1989-01-20 1990-07-26 Hoechst Ag Alkylierte polyethyleniminderivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel sowie pharmazeutische praeparate
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5153184A (en) 1989-10-10 1992-10-06 Dowelanco ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
US5075293A (en) 1989-10-10 1991-12-24 The Dow Chemical Company ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
FR2661676A1 (fr) 1990-05-02 1991-11-08 Lipha Derives d'amino benzocycloalcanes, procedes de preparation et medicaments les contenant.
WO1992017467A1 (en) 1991-04-06 1992-10-15 Dr Lo. Zambeletti S.P.A. Substituted azacyclic compounds, process for their preparation and their use as analgesics
EP0508425A1 (en) 1991-04-12 1992-10-14 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
AU1532492A (en) 1991-04-18 1992-11-17 Dr. Lo Zambeletti S.P.A. Use of heterocyclic compounds for the treatment of inflammatory pain
JP2708633B2 (ja) 1991-05-03 1998-02-04 ライシオン テータート オサケユイチア アクティエボラーグ 血清における高コレステロールレベルを低めるための物質及びその物質を調製するための方法
US5260316A (en) 1991-07-30 1993-11-09 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
ATE162525T1 (de) 1991-07-30 1998-02-15 Ciba Geigy Ag Heteroaryl substituierte hydroxylaminderivate als lipoxygenase-inhibitoren
US5334600A (en) 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
US5350761A (en) 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
EP0534316A1 (de) 1991-09-21 1993-03-31 Hoechst Aktiengesellschaft Verwendung von alkylierten Polyethyleniminderivaten zur Anreicherung von Gallensäuren
US5519001A (en) 1991-12-19 1996-05-21 Southwest Foundation For Biomedical Research CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
FI108451B (fi) 1991-12-20 2002-01-31 Hoechst Ag Menetelmõ polymeeristen ja oligomeeristen sappihappojohdannaisten valmistamiseksi
EP0548793A3 (en) 1991-12-20 1995-11-02 Hoechst Ag Ethylenic-unsaturated bile acid derivatives, process for their production and preliminary processes therefor
DK0548794T3 (da) 1991-12-20 1999-12-06 Aventis Res & Tech Gmbh & Co Polyaspartamidderivater som adsorptionsmidler for galdesyrer, polyaspartamidderivater ladet med galdesyrer, fremgangsmåder
US5244887A (en) 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
ES2159283T3 (es) 1992-02-29 2001-10-01 Aventis Res & Tech Gmbh & Co Complejos que contienen glicosil-fosfatidilinositol-proteinas y derivados de acido colanico, procedimiento para su preparacion y su utilizacion.
DK0563731T3 (da) 1992-03-28 1996-03-18 Hoechst Ag Lægemidler indeholdende polyhydromethylenderivater, fremgangsmåde til deres fremstilling og deres anvendelse
AU675430B2 (en) 1992-04-22 1997-02-06 Ligand Pharmaceuticals Incorporated Compounds having selectivity for retinoid X receptors
CA2093577C (en) 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
FR2698873B1 (fr) 1992-12-07 1995-02-24 Lipha Benzocycloheptènes, benzoxépines et benzothiépines activateurs des canaux potassiques, procédé de préparation, composition pharmaceutique les contenant.
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
EP0646570B1 (en) 1993-04-16 1998-06-24 Shionogi & Co., Ltd. Process for producing lignan compound
EP0624593A3 (de) 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
TW289020B (hu) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
TW289021B (hu) 1993-05-08 1996-10-21 Hoechst Ag
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
IT1273751B (it) 1994-02-11 1997-07-10 Smithkline Beecham Farma Derivati azaciclici
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
WO1996008484A1 (en) 1994-09-13 1996-03-21 Monsanto Company Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5705524A (en) 1994-11-04 1998-01-06 Gilead Sciences, Inc. Thiepane compounds
US6034118A (en) 1994-11-04 2000-03-07 Gilead Sciences, Inc. Thiepane compounds
GB9423172D0 (en) 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines
WO1996040255A2 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
TW513398B (en) 1995-07-21 2002-12-11 Hafslund Nycomed Pharma Novel derivatives of benzenesulfonic acids
GB2305665A (en) 1995-09-26 1997-04-16 Merck & Co Inc Selective ß3 agonists for the treatment of diabetes aand obesity
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
ES2198613T3 (es) 1997-03-14 2004-02-01 Aventis Pharma Deutschland Gmbh 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos.
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
US5929062A (en) 1997-06-19 1999-07-27 University Of Western Ontario Oxysterol inhibition of dietary cholesterol uptake
GB2329334A (en) 1997-09-18 1999-03-24 Reckitt & Colmann Prod Ltd Cholesterol-lowering agents
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
BR9916484A (pt) 2002-01-22
EP1140190B1 (en) 2002-11-20
US6562860B1 (en) 2003-05-13
KR20010102965A (ko) 2001-11-17
HUP0104745A3 (en) 2003-01-28
NZ512535A (en) 2003-12-19
AU776953B2 (en) 2004-09-30
NO20013159D0 (no) 2001-06-22
IL143943A0 (en) 2002-04-21
PT1140190E (pt) 2003-02-28
DK1140190T3 (da) 2002-12-23
EA200100702A1 (ru) 2001-12-24
EP1140190A1 (en) 2001-10-10
JP2002533414A (ja) 2002-10-08
HK1044292A1 (zh) 2002-10-18
ATE228012T1 (de) 2002-12-15
AU2348000A (en) 2000-07-31
AR022022A1 (es) 2002-09-04
DE69904079T2 (de) 2003-07-17
NO20013159L (no) 2001-08-22
PL348609A1 (en) 2002-06-03
CZ20012345A3 (cs) 2001-12-12
ES2189529T3 (es) 2003-07-01
DE69904079D1 (de) 2003-01-02
EA004877B1 (ru) 2004-08-26
CN1338945A (zh) 2002-03-06
CA2356156A1 (en) 2000-07-06
MXPA01006470A (es) 2003-06-06
WO2000038728A1 (en) 2000-07-06
US20040029845A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
HUP0104745A2 (hu) Csípőbél epesav transzport inhibitorok és epesav elvonószerek kombinációi szív-érrendszeri indikációkhoz
HUP0104593A2 (hu) Csípőbél epesav transzport inhibitor benzotiepin- és nikotinsav-származékok kombinációi szív-érrendszeri indikációkhoz
MXPA01006472A (es) Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares.
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
DK0695189T3 (da) Behandling af inflammatorisk tarmsygdom med IFN-gammainhibitorer
MXPA01006471A (es) Combinaciones de inhibidores de transporte de acido biliar ileal e inhibidores de proteina de transferencia de ester colesterilio cpara indicaciones cardiovasculares.
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
AP2003002743A0 (en) Therapeutic combination of a cept inhibitor and atorvastatin
DE69827777D1 (de) Zusammensetzungen mit verzögerter Wirkstoffabgabe zur Behandlung der Hyperlipidämie
DE69827821D1 (de) Synergistisch,analgetische zusammensetzung mit opiod-analgetika und zyklooxygenase-2 inhibitoren
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
DK1216038T3 (da) Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
WO2000035436A3 (en) Treatment of arthritis with mek inhibitors
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
EP1776954A3 (en) The use of inhibitors of the renin-angiotensin system for the treatment of stroke
WO2001085201A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
MXPA02012713A (es) Combinacion de inhibidores de fructosabisfosfatasas y agentes antidiabeticos, util para el tratamiento de la diabetes.
GB9804886D0 (en) Therapeutic combination
BR9713522A (pt) Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.
HUP0400886A2 (hu) Koleszteril-észter transzfer protein inhibitorok és fibrinsav-származékok kombinációi szív-érrendszeri indikációkhoz
EP0870502A3 (en) Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis
DK0866699T3 (da) Anvendelse af cholinesteraseinhibitorer til fremstilling af et medikament til behandling af xerostomi
NZ328198A (en) a pharmaceutical composition containing hydroxyzine and a serotonin uptake inhibitor
AU2157500A (en) Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications